Sarepta Therapeutics (SRPT) – Analyst EPS Change
-
Roche hits 5-year lows on disappointing study results, JPMorgan's bearish comments
-
Sarepta Therapeutics (SRPT) PT Lowered to $150 but Needham & Company Offers 4 Reasons to be Bullish into the 2-Year Update
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SRPT Stock Lookup